Healthy AdultsNCT06021223
The Effects of Chicken Extract on Mental Energy in Healthy Adults and the Underlying Mechanisms
A study testing Chicken extract supplement (high-dose) and Chicken extract supplement (low-dose) in people with Healthy Adults, run by Brand's Suntory Asia at 1 site in Taiwan.
Trial summary
This exploratory trial investigates the effect of a chicken extract supplement on mental energy and its potential underlying mechanisms of action among healthy adults using a randomized, double-blind, placebo-controlled clinical trial design. Read more about this study
- Who is it for?
- Ages 35 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adults
- What is being tested?
- Chicken extract supplement (high-dose) and Chicken extract supplement (low-dose)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 189 participants
- Where
- 1 siteTaiwan
- Study dates
- 22 Aug 2023to 8 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male or female at 35-64 years of age
- Assessed by investigator to be in good health
- Normal cognition based on investigator's clinical judgement per the routine practice
- Modified PSQI score > 5
- Agree to participate in the study and provide written informed consent
- Agree to abstain from herbal extracts or dietary supplements throughout the study period
Who cannot join
- BMI < 18.5 or ≥ 27 kg/m2
- Concurrent pharmacological treatments
- Current systemic diseases or current/history of neurological or cerebrovascular diseases
- Active peptic ulcer, or a history of peptic ulcer within the last 2 years
- Medications or interventions in the last 4 weeks, which in the investigators' judgement could potentially affect the outcome measures
- Regular significant quantities of dietary supplements or herbal extracts (> 2 times a week) in the last 4 weeks
Show all 17Show fewer
- Regular excessive caffeine consumption, heavy alcohol consumption or heavy habitual smokers
- Any drastic changes in lifestyle (including diet, smoking, sleep, exercise, and mental and physical activities) in the last 4 weeks
- Not able to maintain the same lifestyle throughout the study period
- Inadequate visual and auditory acuity to allow neuropsychological testing per investigator's judgment
- Inability to undergo fMRI scan
- Any consumption of chicken extract supplement, or carnosine or anserine supplement, in the preceding 4 weeks
- History of allergy to caseinate, milk, or chicken meat
- Women who are pregnant or lactating or intending to do so
- Current enrolment in another interventional study
- Subjects who show unstable sleep habits during the previous month
- Excessive blood donation or blood drawn prior to baseline
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Taipei Medical University Hospital Shuang Ho Hospital
New Taipei City, 235
About this study
Official title: Trial of a Chicken Extract for Improving Mental Energy and Mechanisms of Action in Healthy Adults: A Randomized, Double-blind, Placebo-controlled Exploratory Study
This exploratory trial investigates the effect of a chicken extract supplement on mental energy and its potential underlying mechanisms of action among healthy adults using a randomized, double-blind, placebo-controlled clinical trial design. Mental energy is a multi-dimensional construct comprising transient feelings about fatigue, vigor and motivation and cognitive performance in terms of sustained attention and reaction time.
A sub-study investigates the immediate biochemical changes after taking chicken extract.
- Conditions
- Healthy Adults
- Being tested
- Chicken extract supplement (high-dose), Chicken extract supplement (low-dose), Placebo
- Keywords
- Mental energy, Chicken extract, Mechanisms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chicken extract supplement (high-dose)Dietary supplement
140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
Chicken extract supplement (low-dose)Dietary supplement
140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
PlaceboOther
140ml of placebo to be consumed daily for 2 weeks
| Study group | Role | What they receive |
|---|---|---|
| Chicken extract supplement (high-dose) | Experimental | 140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks Receives: Dietary Supplement: Chicken extract supplement (high-dose) |
| Chicken extract supplement (low-dose) | Experimental | 140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks Receives: Dietary Supplement: Chicken extract supplement (low-dose) |
| Placebo | Placebo comparator | 140ml of placebo (caesinate) to be consumed daily for 2 weeks Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reaction time and sustained attention (composite) assessed by Cogstate Brief Battery (CBB)
Measured: At baseline and on Day 14
Reaction time assessed by Deary-Liewald reaction time task
Measured: At baseline and on Day 14
Sustained attention assessed by psychomotor vigilance test
Measured: At baseline and on Day 14
Sustained attention assessed by trail making test
Measured: At baseline and on Day 14
Fatigue assessed by Profile of Mood States (POMS)
POMS-fatigue scores range from 0 to 24, with higher score indicating greater fatigue.
Measured: Daily from baseline to Day 14
Fatigue assessed by visual analogue scale (VAS)
VAS scores range from 0 to 100, with higher score indicating greater fatigue.
Measured: Daily from baseline to Day 14
Vigor assessed by Profile of Mood States (POMS)
POMS-vigor scores range from 0 to 28, with the higher score indicating greater vigor.
Measured: Daily from baseline to Day 14
Vigor assessed by visual analogue scale (VAS)
VAS scores range from 0 to 100, with higher score indicating greater vigor.
Measured: Daily from baseline to Day 14
Motivation assessed by visual analogue scale (VAS)
VAS scores range from 0 to 100, with higher score indicating greater motivation.
Measured: Daily from baseline to Day 14
Cerebral blood flow using arterial spin labelling magnetic resonance imaging (MRI)
Measured: At baseline and on Day 14
Cerebral oxygenation using functional MRI blood oxygenation level dependent (BOLD) imaging
Measured: At baseline and on Day 14
Whole body metabolic rate using indirect calorimetry
Resting body metabolic rate will be measured
Measured: At baseline and on Day 14
Plasma global metabolome (metabolic profile) using liquid chromatography mass spectrometry (LCMS)
Plasma samples will be analyzed to putatively identify biomarkers of product intake by comparison of test group with control group using high-performance liquid chromatography coupled to mass spectrometer (LCMS). LCMS analysis allows the simultaneous and non-targeted analysis of a wide array of endogenous and exogenous metabolites.
Measured: At baseline and on Day 14
Salivary cortisol level
Measured: At baseline and on Day 14
Plasma carnosine
Measured: At baseline and on Day 14
Plasma anserine
Measured: At baseline and on Day 14
Plasma L-histidine
Measured: At baseline and on Day 14
Plasma methylhistidine
Measured: At baseline and on Day 14
Plasma beta-alanine
Measured: At baseline and on Day 14
Secondary outcomes (1)
Sleep quality measured by modified Pittsburgh Sleep Quality Index (PSQI)
In the PSQI, scores from the individual items are used to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score, with a range of 0-21 points, with higher scores indicating poorer sleep quality. The modified PSQI measures the sleep quality in the past two weeks.
Measured: At baseline and on Day 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2023
- Study start22 Aug 2023
- Primary completion8 Jan 2025
- Study completion8 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 189 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brand's Suntory Asia
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Taipei Medical University Shuang Ho Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06021223
- Sponsor's protocol ID
- BEC-002
- Status last verified
- Jan 2025
- First submitted
- 22 Aug 2023
- Last updated
- 16 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Trial of a Chicken Extract for Improving Mental Energy and Mechanisms of Action in Healthy Adults: A Randomized, Double-blind, Placebo-controlled Exploratory Study
- ClinicalTrials.gov ID
- NCT06021223
- Acronym / sponsor ID
- BEC-002
- Conditions
- Healthy Adults
- Keywords
- Mental energy, Chicken extract, Mechanisms
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 189 participants (actual)
- Lead sponsor
- Brand's Suntory AsiaIndustry (pharma, biotech, devices)
- Collaborators
- Taipei Medical University Shuang Ho Hospital
- Study start
- 22 Aug 2023 (actual)
- Primary completion
- 8 Jan 2025 (actual)
- Study completion
- 8 Jan 2025 (actual)
- First posted
- 1 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This exploratory trial investigates the effect of a chicken extract supplement on mental energy and its potential underlying mechanisms of action among healthy adults using a randomized, double-blind, placebo-controlled clinical trial design. Mental energy is a multi-dimensional construct comprising transient feelings about fatigue, vigor and motivation and cognitive performance in terms of sustained attention and reaction time.
A sub-study investigates the immediate biochemical changes after taking chicken extract.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Chicken extract supplement (high-dose) | Experimental | Dietary Supplement: Chicken extract supplement (high-dose)140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks |
| Chicken extract supplement (low-dose) | Experimental | Dietary Supplement: Chicken extract supplement (low-dose)140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks |
| Placebo | Placebo comparator | Other: Placebo140ml of placebo (caesinate) to be consumed daily for 2 weeks |
Who may qualify
- Ages
- 35 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Male or female at 35-64 years of age
- Assessed by investigator to be in good health
- Normal cognition based on investigator's clinical judgement per the routine practice
- Modified PSQI score > 5
- Agree to participate in the study and provide written informed consent
Key exclusion criteria (17 listed)
- BMI < 18.5 or ≥ 27 kg/m2
- Concurrent pharmacological treatments
- Current systemic diseases or current/history of neurological or cerebrovascular diseases
- Active peptic ulcer, or a history of peptic ulcer within the last 2 years
- Medications or interventions in the last 4 weeks, which in the investigators' judgement could potentially affect the outcome measures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chicken extract supplement (high-dose)140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks | Dietary supplement | Chicken extract supplement (high-dose) |
| Chicken extract supplement (low-dose)140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks | Dietary supplement | Chicken extract supplement (low-dose) |
| Placebo140ml of placebo to be consumed daily for 2 weeks | Other | Placebo |
Primary outcome
Reaction time and sustained attention (composite) assessed by Cogstate Brief Battery (CBB)
Time frame: At baseline and on Day 14
Reaction time assessed by Deary-Liewald reaction time task
Time frame: At baseline and on Day 14
Sustained attention assessed by psychomotor vigilance test
Time frame: At baseline and on Day 14
Sustained attention assessed by trail making test
Time frame: At baseline and on Day 14
Fatigue assessed by Profile of Mood States (POMS)
Time frame: Daily from baseline to Day 14
POMS-fatigue scores range from 0 to 24, with higher score indicating greater fatigue.
Fatigue assessed by visual analogue scale (VAS)
Time frame: Daily from baseline to Day 14
VAS scores range from 0 to 100, with higher score indicating greater fatigue.
Vigor assessed by Profile of Mood States (POMS)
Time frame: Daily from baseline to Day 14
POMS-vigor scores range from 0 to 28, with the higher score indicating greater vigor.
Vigor assessed by visual analogue scale (VAS)
Time frame: Daily from baseline to Day 14
VAS scores range from 0 to 100, with higher score indicating greater vigor.
Motivation assessed by visual analogue scale (VAS)
Time frame: Daily from baseline to Day 14
VAS scores range from 0 to 100, with higher score indicating greater motivation.
Cerebral blood flow using arterial spin labelling magnetic resonance imaging (MRI)
Time frame: At baseline and on Day 14
Cerebral oxygenation using functional MRI blood oxygenation level dependent (BOLD) imaging
Time frame: At baseline and on Day 14
Whole body metabolic rate using indirect calorimetry
Time frame: At baseline and on Day 14
Resting body metabolic rate will be measured
Plasma global metabolome (metabolic profile) using liquid chromatography mass spectrometry (LCMS)
Time frame: At baseline and on Day 14
Plasma samples will be analyzed to putatively identify biomarkers of product intake by comparison of test group with control group using high-performance liquid chromatography coupled to mass spectrometer (LCMS). LCMS analysis allows the simultaneous and non-targeted analysis of a wide array of endogenous and exogenous metabolites.
Salivary cortisol level
Time frame: At baseline and on Day 14
Plasma carnosine
Time frame: At baseline and on Day 14
Plasma anserine
Time frame: At baseline and on Day 14
Plasma L-histidine
Time frame: At baseline and on Day 14
Plasma methylhistidine
Time frame: At baseline and on Day 14
Plasma beta-alanine
Time frame: At baseline and on Day 14
1 secondary outcome
Sleep quality measured by modified Pittsburgh Sleep Quality Index (PSQI)
Time frame: At baseline and on Day 14
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Healthy Adults
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chicken extract supplement (high-dose) and Chicken extract supplement (low-dose) in people with Healthy Adults, run by Brand's Suntory Asia at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reaction time and sustained attention (composite) assessed by Cogstate Brief Battery (CBB) (time frame: At baseline and on Day 14). The study lists 19 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.